Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives by Üner, Melike & Yener, Gülgün
© 2007 Dove Medical Press Limited.   All rights reserved
International Journal of Nanomedicine 2007:2(3) 289–300 289
REVIEW
Importance of solid lipid nanoparticles (SLN) 
in various administration routes and future 
perspectives
Melike Üner
Gülgün Yener
1Istanbul University, Faculty 
of Pharmacy, Department of 
Pharmaceutical Technology, Beyazit 
34119 Istanbul, Turkey
Correspondence: Melike Üner
Istanbul University, Faculty of Pharmacy, 
Department of Pharmaceutical 
Technology, Beyazit 34119 Istanbul, Turkey
Tel +90 2124 400250
Fax +90 2124 400252
Email melikeuner@yahoo.com
Abstract: Solid lipid nanoparticles (SLN) have been reported to be an alternative system to 
emulsions, liposomes, microparticles and their polymeric counterparts for various applica-
tion routes since the early 1990s due to their advantages. Various research groups have also 
increasingly focused on improving their stability in body ﬂ  uids after administration by coating 
of particles with hydrophilic molecules such as poly(ethylene)glycol (PEG) derivatives. Altering 
surface characteristics by coating SLN with hydrophilic molecules improves plasma stability 
and biodistribution, and subsequent bioavailability of drugs entrapped. Their storage stability is 
also increased. This paper basicly reviews types of SLN, principles of drug loading and models 
of drug incorporation. The inﬂ  uence of PEG coating on particle size and surface characteristics 
is discussed followed by alteration in pharmacokinetics and bioavailability of drugs in order 
to target the site of action via SLN. The future direction of research and clinical implications 
of SLN is also considered.
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Introduction
Great progress has been made in the treatment of a variety of diseases by using drug 
delivery systems including solid lipid nanoparticles (SLN). SLN are colloidal drug 
carrier systems (Mehnert and Mäder 2001; Müller and Keck 2004; Castelli et al 2005). 
They are very much like nanoemulsions, differing in lipid nature. The liquid lipid used 
in emulsions is replaced by a lipid solid at room temperature in SLN including high-
melting point glycerides or waxes (Siekmann and Westesen 1992; Müller and Keck 2004; 
Manjunath and Venkateswarlu 2005). They are increasing in signiﬁ  cance as alternative 
drug carriers to polymeric nanoparticles. Controlled drug delivery, enhancement of 
bioavailability of entrapped drugs via modiﬁ  cation of dissolution rate (Demirel et al 
2001) and/or improvement of tissue distribution and targeting of drugs (Göppert and 
Müller 2005) by using SLN have been reported in various application routes:
–  Parenteral (intravenously, intramuscularly or subcutaneously) (Yang et al 1999a; 
Wissing et al 2004),
–  Oral (Yang et al 1999b; Pandey et al 2005),
–  Rectal (Sznitowska et al 2001),
–  Opthalmic (Cavalli et al 2002; Friedrich et al 2005),
–  Topical (in cosmetics and dermatological preparations) (De Vringer and De Ronde 
1995; Dingler et al 1998; Lippacher et al 2002; Münster et al 2005).
Indeed, nanoparticles were initially thought to be designed as carriers for 
vaccines and anticancer drugs when they were ﬁ  rst developed in about 1970. In the 
strategy of drug targeting in order to enhance tumor uptake, researchers focused International Journal of Nanomedicine 2007:2(3) 290
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on the development methods to reduce the uptake of the 
nanoparticles by the cells of the reticuloendothelial system 
(RES) as the ﬁ  rst important step. As one of those methods, 
coating of nanoparticles and nanocapsules with hydrophilic 
substances such as polyoxypropylene block copolymers 
(poloxamers) (Göppert and Müller 2005), chitosan (Garcia-
Fuentes et al 2005a), polyvinyl alcohol (Pandey et al 2005) 
and PEG (De Campos et al 2003) has a clear beneﬁ  t in their 
ability to reduce the phagocytic uptake with a minimal non-
speciﬁ  c interaction with other proteins. Increasing attention 
has also been paid to the coating of SLN to provide receptor 
mediated drug and gene delivery in recent years (Kakizawa 
and Kataoka 2002; Garcia-Garcia et al 2005). Coating of 
colloidal carriers has been demonstrated to improve stabil-
ity of the particles and to enhance transmucosal transport 
of the associated compounds following either nasal (Vila 
et al 2004), oral (Jani et al 1990) or ocular administration 
(De Campos et al 2001).
Several innovative reviews on solid lipid nanotechnology 
for drug delivery are available in the literature which describes 
extensive preparation techniques, characterization and types 
of SLN, investigation of their structural properties, factors 
affecting their formation and storage stability, drug loading 
principles and drug release characteristics (Müller et al 2000; 
Mehnert and Mäder 2001; Müller et al 2002a; Müller et al 
2002b; Heurtault et al 2003; Müller and Keck 2003; Uner 
2006). This paper reviews hydrophilic surface coating of SLN 
among various approaches in order to improve efﬁ  ciency of 
drugs incorporated. Brief description of production methods, 
types of SLN and consequently principles of drug release are 
given. Alteration in particle size and surface characteristics of 
SLN by PEG coating is described, followed by the beneﬁ  ts 
of this surface modiﬁ  cation in various administration routes, 
the effect of coating on bioavailability of drugs incorporated 
and the future direction of research.
Production methods of SLN
SLN are produced by using several methods extensively 
described in the literature:
–  High pressure homogenization (cold and hot homogeni-
zation) (Müller and Runge 1998; Jores et al 2004; Üner 
et al 2005b),
–  Breaking of o/w microemulsion (Gasco 1993; Cavalli 
et al 1997; Cavalli et al 1999; Igartua et al 2002),
– Solvent  emulsiﬁ  cation-evaporation (Sjostrom and Ber-
genståhl 1992; Cortesi et al 2002; Shahgaldian et al 2003) 
or solvent emulsiﬁ  cation–diffusion (Quintanar-Guerrero 
et al 2005; Hu et al 2005),
–  Solvent injection (Schubert and Müller-Goyman 2003),
–  Preparation via water-in-oil-in-water double emulsion 
(w/o/w) (Morel et al 1998; Cortesi et al 2002),
–  High shear homogenization (Kržič et al 2001) and/or ultra-
sound dispersion (Mei et al 2003; Song and Liu 2005),
–  Preparation by using membrane contactor as a new reported 
technique for SLN production (Charcosset et al 2005).
Today, the high pressure homogenization technique has 
been demonstrated to be the most effective technique due 
to some advantages such as narrow particle size distribution 
of the product with a low content of microparticles (> 5 μm 
is requested for iv injections), higher particle content in the 
dispersions, avoidance of organic solvents, acceptability of 
the homogenization equipment by the regulatory authorities 
(even for parenteral products), scale-up feasibility and the 
availability of homogenization lines in industry (Müller 
and Runge 1998; Gohla and Dingler 2001; Mehnert and 
Mäder 2001). Depending on the size of production-scale 
homogenizers, a wide production range can be possible 
(Müller and Keck 2004; Wissing et al 2004).
Drug incorporation models 
and types of SLN
Factors affecting loading capacity of a drug in lipid are 
(Müller et al 2000):
–  solubility of drug in lipid melt,
–  miscibility of drug melt and lipid melt,
–  chemical and physical structure of solid matrix lipid,
–  polymorphic state of lipid material.
In particular, there is an inverse relationship between 
solubility of the drug and loading capacity. Enhancement 
in aqueous solubility of drug leads lower to entrapment 
efﬁ  ciency. For this reason, Müller et al reported a cold 
homogenization technique which is performed at room 
temperature or below (0 °C) (Müller et al 1995; Müller and 
Hildebrand 1997). Therefore, solubility of the drug is also 
an important factor for choosing the production method of 
SLN. While the hot homogenization technique is much more 
suitable for lipophilic drugs, the cold homogenization tech-
nique is employed for hydrophilic drugs in order to reach the 
highest payload and to prevent drug partition to the aqueous 
phase during SLN production.
Drug incorporation models of SLN are (Figure 1):
–  solid solution model 
–  core-shell model (drug-enriched shell and drug-enriched 
core )
In the case of the solid solution model, the drug is 
molecularly dispersed in the lipid matrix when the particles International Journal of Nanomedicine 2007:2(3) 291
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are produced by the cold homogenization technique and using 
no surfactant or no drug-solubilizing surfactant. The drug 
has strongly pronounced interactions with the lipid (Schwarz 
1995; Zur Mühlen et al 1998).
According to the drug-enriched shell model of drug incor-
poration, a solid lipid core forms when the recrystallization 
temperature of the lipid is reached. On reducing the temperature 
of the dispersion, the drug concentrates in the still liquid outer 
shell of the SLN (Heiati et al 1997; Müller et al 2002a).
According to the drug-enriched core model of drug 
incorporation, cooling the nanoemulsion leads to a super-
saturation of the drug which is dissolved in the lipid melt at 
or close to its saturation solubility and the drug precipitates 
prior to lipid recrystallization. Further cooling ﬁ  nally leads 
to the recrystallization of the lipid surrounding the drug as a 
membrane (Müller et al 2000).
A SLN modiﬁ  ed by incorporation of liquid lipid into the 
solid structure has been proposed as nanostructured lipid 
carriers (NLC) to overcome some limitations related to old 
generation SLN. Müller et al described NLC with a special 
structure for better drug accommodation in order to increase 
the payload and prevent drug expulsion during storage. NLC 
combine controlled drug release characteristics with some 
advantages over SLN. NLC have so far been studied for 
topical use, but they offer all the advantages and production 
aims of SLN. Three types of NLC have been described: I) 
imperfect type, II) amorphous type and III) multiple type 
(Figure 2) (Radtke and Müller 2001; Müller et al 2002a; 
Müller et al 2002b).
I) Imperfect type NLC (imperfectly structured solid 
matrix): Spatially different lipids are mixed, and thus 
imperfections in the crystal order of lipid nanoparticles 
are provided. Large distances between fatty acid chains 
in the matrix structure of lipid nanoparticles can be in-
creased by using glycerides composed of very different 
fatty acids. Therefore, the matrix contains imperfec-
tions to accommodate the drug in amorphous clusters 
(Figure 1, upper). Mixing small amounts of chemically 
very different liquid lipids (oils) with solid lipids in order 
to achieve the highest incompatibility leads the highest 
drug payload.
II) Amorphous type (structureless solid amorphous matrix): 
This kind of NLC can be achieved by mixing solid lipids 
with special lipids, eg, hydroxyoctacosanylhydroxystea-
rate, isopropylmyristate or medium chain triglycerides 
such as Miglyol® 812. Therefore, drug expulsion caused 
by the process of crystallization to β forms during storage 
is prevented by the special structure of the lipid matrix 
since NLC are solids in an amorphous but not crystalline 
state (Figure 1, middle) (Radtke and Müller 2001).
III) Multiple type (multiple oil in fat in water (O/F/W) 
carrier): The solubility of the drug in the lipophilic 
phase decreases during the cooling process after 
homogenization and the crystallization process during stor-
age. Continuously reducing drug solubility leads to drug 
expulsion from the lipid nanoparticles especially when the 
drug concentration in the formulation is too high. Solubility 
of many drugs in a liquid lipid is higher than in a solid lipid. 
Figure 1 Models of drug incorporation into SLN: homogeneous matrix of solid 
solution (upper), drug-free core with drug-enriched shell (middle), drug-enriched 
core with lipid shell (lower).
solid solution
drug-enriched shell
drug-enriched core
core-shell model
imperfect type (I)
amorphous type (II)
multiple type (III)
amorphous lipid
oil nanocompartments
solid lipid
drug
Figure 2 Types of NLC: (I) imperfect type, (II) amorphous type and (III) multiple 
type.International Journal of Nanomedicine 2007:2(3) 292
Üner and Yener
When lipids lack appropriate drug solubilities, addition 
of a higher amount of liquid lipid to the lipophilic phase 
displays the advantages of the solid matrix which prevented 
drug leakage while the liquid regions (oily nanocompart-
ments) show comparatively high solubility for lipophilic 
drugs (Figure 1, lower) (Jenning et al 2000b).
Principles of drug release from SLN
The general principles of drug release from lipid nanoparticles 
are as follows (Zur Mühlen and Mehnert 1998; Müller et al 
2002a; Venkateswarlu and Manjunath 2004; Uner 2006);
–  There is an inverse relationship between drug release and 
the partition coefﬁ  cient of the drug.
–  Higher surface area due to smaller particle size in nano-
meter range gives higher drug release.
–  Slow drug release can be achieved when the drug is 
homogenously dispersed in the lipid matrix. It depends 
on type and drug entrapment model of SLN.
–  Crystallinization behaviour of the lipid carrier and high 
mobility of the drug lead to fast drug release. There is an 
inverse relationship between crystallization degree and 
mobility of drug.
The drug incorporation model of SLN is crucial to the 
drug release pattern. It is related to the composition and 
production method of SLN as explained above. For instance, 
the drug-loaded lipid phase remains mainly in the solid state 
in the case of production by cold homogenization technique. 
The solid solution drug incorporation model appears here. 
Drug release is prolonged over several weeks since mobility 
of the drug molecularly dispersed in colloidal particles is very 
limited (Müller et al 1994).
Fast initial drug release (burst effect) exists in the ﬁ  rst 
5 minutes in the drug-enriched shell model (ie, about 100% 
within <5 min) as a result of the outer layer of the particles 
due to the large surface area of drug depositon on the particle 
surface (Müller et al 1994; Zur Mühlen and Mehnert 1998). 
The burst release is reduced with increasing particle size 
and prolonged release could be obtained when the particles 
were sufﬁ  ciently large, ie, lipid microparticles (Schwarz 
et al 1994; Müller et al 1995). The type of surfactant and its 
concentration, which will interact with the outer shell and 
affect its structure, should be noted as the other important 
factor, because a low surfactant concentration leads to a 
minimal burst and prolonged drug release.
In the drug-enriched core model, the drug release is mem-
brane controlled and is governed by the Fick law diffusion 
since the lipid surrounds the drug as a membrane (Müller 
et al 2000).
In the case of NLC – the new generation SLN – the oil 
content of the particles solves the drug and combines con-
trolled release characteristics with high drug loading capac-
ity. Müller et al (2002b) reported that the imperfect type and 
amorphous type of NLC, in particular, provide much more 
ﬂ  exibility to achieve the desired prolonged release.
The particle size that affects drug release rate directly 
depends on various parameters such as composition of SLN 
formulation (such as surfactant/surfactant mixture, amount 
of drug incorporated, structural properties of lipid and drug), 
production methods and conditions (such as time, production 
temperature, equipment, sterilization and lyophilization). 
All those parameters have been extensively investigated and 
data have been reported in the literature for years (Siekmann 
and Westesen 1992; Cavalli et al 1997; Freitas and Müller 
1998; Liedtke et al 2000; Mehnert and Mäder 2001; Hou 
et al 2003; Schubert et al 2006). Additionally, surface 
modiﬁ  ers to reduce phagocytic uptake such as polyethylene 
oxide and PEG may change the particle size. The effect of 
surface modiﬁ  ers on particle size and on drug release rate is 
discussed in upcoming sections.
Coating of solid lipid nanoparticles 
(SLN) with hydrophilic substances
In case of systemic use, ideal drug delivery is selective uptake 
by the target organ or at the site of action with a low systemic 
level of drug. It is very difﬁ  cult to provide this ideal situation 
in practice because anatomical barriers limit and govern the 
distribution of drugs. SLN which are hydrophobic, are exposed 
to phagocytic uptake by macrophages. Studies on systemic 
use of SLN have focused on improving their presence in the 
blood circulation since macrophages in RES recognize them 
as foreign substances and quickly remove them due to their 
physicochemical properties, mainly particle size, surface 
charge and surface hydrophobicity (Illum et al 1987; Müller 
1991; Bocca et al 1998). Uptake by phagocytic cells is mediated 
by blood components which are called opsonins and speciﬁ  c 
cell receptors on macrophages that operate independently. The 
opsonic factors include proteins such as immunoglobulin G, 
Complement C3b and ﬁ  bronectin. These factors are adsorbed 
by nanoparticles, then the particles are immediately cleared 
by the macrophages of the mononuclear phagocytic system 
(Müller et al 1997). The surface characteristics of the particle 
determine whether or not opsonization will take place and 
which component will be involved. As a consequence, the 
mechanism of particle-cell interaction will also depend on the 
nature of the opsonic component and the relevant receptor-
mediated process (Wright and Illum 2000).International Journal of Nanomedicine 2007:2(3) 293
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To avoid phagocytic uptake and to modulate biodistribution 
parameters of drugs for their long blood circulation, surface 
properties of colloidal drug carriers can be modiﬁ  ed by using 
various techniques. Of the many techniques used to enhance 
the blood circulation time of particles, surface coating with 
polyethylene glycol (PEG) polymers has been reported to 
be successful (Yuda et al 1996; Heiati et al 1998; Dierling 
et al 2006). Abuchowski et al (1977) decreased immunologi-
cal properties of bovine serum albumin by using PEG. This 
technique has started to be used to decrease the immuno-
genicity of proteins including enzymes such as superoxide 
dismutase (Gray and Stull 1983), arginase (Savoca et al 
1984) and asparaginase (Abuchowski et al 1984; Wright 
and Illum 2000). A decrease was observed in recognition of 
PEG-modiﬁ  ed proteins by macrophages. The same mecha-
nism was thought to be used for particles to increase their 
biodistribution. When the particles are coated with PEG, it 
can favourably modify the surface hydrophobicity of particles 
and sterically stabilize them, thus suppressing the binding of 
serum proteins (eg, apoproteins) and other opsonic factors 
(Heurtault et al 2003; Garcia-Fuentes et al 2005a; Dierling 
et al 2006). Sterically stabilized SLN have also been called 
stealth SLN, but conversely non-stealth SLN by various 
research groups (Bocca et al 1998; Fundaro et al 2000).
PEG derivatives at various molecular weights which 
are block copolymers, chemically contain hydrophilic and 
hydrophobic residues that give them amphiphilic character-
istics. In an aqueous PEG coated SLN dispersion, soluble 
hydrophilic residue of PEG turns to the water phase and 
insoluble hydrophobic residue is oriented on the lipophilic 
SLN by formation of a shell around it (Figure 3).
Effect of PEG coating on 
physical properties of SLN and 
bioavailability of drugs
In general, surface modiﬁ  cation of colloidal particles by 
coating with a hydrophilic substance like PEG reported to 
bring following beneﬁ  ts
–  Providing good physical stability and dispersability of 
colloids (Acar et al 2005; Zhang and Zhang 2005),
–  Improving presence of colloids in blood circulation for 
systemic use (Moghimi et al 1994; Gref et al 1995),
–  Increasing stability of colloids in body ﬂ  uids such as GI 
ﬂ  uids (Garcia-Fuentes et al 2005a),
–  Acceleration of colloid transport accross the epithelium 
(De Campos et al 2003; Prego et al 2005),
–  Modulation of interaction of colloids with mucosa for 
speciﬁ  c delivery requirements and drug targeting (Otsuka 
et al 2003; Oyewumi et al 2004),
–  Increasing biocompatibility and decreasing thrombo-
genicity of drug carriers (Otsuka et al 2003; Zhang and 
Zhang 2005).
–  Providing reservoir function to colloid particles carrying 
hydrophobic drugs due to hydrophilic coating around the 
particles (Lundberg et al 1996; Heiati et al 1998).
PEG ligands 
Lipophilic residue Hydrophilic residue
PEG coated SLN 
Figure 3 Schematic representation of SLN coated with PEG and molecular residues of PEG.International Journal of Nanomedicine 2007:2(3) 294
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Coating materials are mostly adsorbed on the surface of 
the nanoparticles. Stability of coated particles also depends 
on the strength of the bond between particle and coating. 
In case of PEG, it attaches covalently to the nanoparticle 
surface and provides a hydrophilic steric barrier around 
SLN (Acar et al 2005). This protective layer prevents 
agglomeration during the production and/or storage, and 
subsequently, improves physical stability and dispersability 
of inner phase. Concentration of stealth agents strongly 
affects the rate of the phagocytic uptake. There is an inverse 
relationship between concentration and uptake. Bocca et al 
(1998) studied the phagocytic uptake of PEG-coated dipal-
mitoylphosphatidylamine and stearic acid SLNs by murine 
macrophages. They reported a signiﬁ  cant increase in particle 
size related to the PEG concentration in the formulations and 
a decrease in murine uptake compared with non-stealth SLN. 
Optimum particle size for lymphatic uptake was reported to 
be between 10 and 100 nm and to be selective and slower as 
the particle size increases (Swartz 2001). In general, increase 
in particle size by coating nanoparticles with stabilizing 
hydrophilic molecules leads to extended blood circulation 
of SLN. Various researchers also indicated that the colloidal 
carrier systems are required to possess smaller size, addition-
ally hydrophobicity and strong negative surface charge for 
effective penetration into lymphatic interstitium (Porter 1997; 
Harivardhan Reddy et al 2005).
Heiati et al (1998) determined that PEG coating did not 
changed the particle size of azidothymidine loaded trilaurin 
SLN in their study. The hydrophilic character of coating 
prolonged the release of lipophilic azidothymidine here. PEG 
coating further enhanced the blood level of the drug compared 
to non-stealth SLN and decreased urinary excretion in mice.
Fundaro et al (2000) also observed no change in the 
particle size of SLN. However, the hydrophilic surface 
characteristic of the particles which was provided by PEG, 
reduced the phagocytic recognition in rats. Correlation 
between hydrophobicity and the rate of phagocytosis of col-
loidal particles was observed, as reported in various studies 
(Müller et al 1996a; Harivardhan Reddy et al 2005; Prego 
et al 2005). Although there was a slight alteration in particle 
size (from 80 nm to 90 nm), a ﬁ  ve-fold enhancement of the 
doxorubicin peak plasma concentration was obtained by 
using SLN as a carrier, and a seven-fold enhancement for 
stealth SLN (Fundaro et al 2000). Highest drug concentration 
was observed in the lung with stealth SLN. In brain tissues, 
doxorubicin was determined after administration of stealth 
SLN while the drug was not determined with drug solution 
and nonstealth SLN.
Surface charge of a colloid was reported to strongly 
affect biodistribution and clearance rate of drugs in 1966. 
Thus it was altered by coating, so that plasma half-life of 
the colloids could be increased. Half-life of negatively 
charged colloids was generally found to be higher than that 
of positively charged colloids (Wilkins and Myers 1966). 
However, it should be noted that a strong negative charge or 
a strong positive charge usually leads to phagocytic uptake 
more rapidly than weak negative charge (Stossel et al 1972). 
Zeta potential which indicates the surface characteristics, 
is greatly affected by the nature of coating. A study which 
investigated the surface modiﬁ  cation of PEG-coated SLN, 
uncoated tripalmitin SLN presented a negative charge due 
to the anionic ingredients in their composition (Garcia-
Fuentes et al 2005a). When they were coated with PEG, 
the zeta potential showed a less negative value than that of 
non-stealth SLN. PEG altered zeta potential from –50.3 to 
–34.8 in the negative range. The presence of PEG on the 
surface of SLN partially masked the negative charge of the 
uncoated particles. This effect is common for PEG-coated 
nanoparticles due to an extension of the plane of shear of 
the nanoparticles (Gref et al 2000). Similar results were 
found in various studies on drug carriers (Tröster et al 1992; 
Lundberg et al 1996; Vila et al 2004). In Bocca’s study, zeta 
potential of the stealth SLN (between –38.0 and –32.5 mV) 
was reported to be lower than those of the non-stealth SLN 
(–47.5 mV) indicating the presence of PEG chains on the 
surface (Bocca et al 1998).
Administration routes of solid lipid 
nanoparticles (SLN) and future 
direction of research
Parenteral administration
Peptide and protein drugs are usually available for parenteral 
use in the market. Their conventional oral administration 
is not possible due to enzymatic degradation in GI tract. 
Repeated parenteral administration is necessary since 
their half-lives are too short (a few minutes). To solve 
the problems, improve patient compliance and provide an 
effective treatment, researchers have studied non-parenteral 
administration routes such as transdermal and nasal for years. 
As an alternative, the development of parenteral drug carriers, 
which will provide controlled drug release over a month or 
longer, has been attempted. SLN are promising colloidal drug 
carriers among many other carriers such as their polymeric 
counterparts and liposomes. Wissing et al (2004) intensively 
reviewed parenteral use of SLN. SLN are very suitable for International Journal of Nanomedicine 2007:2(3) 295
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systemic delivery because they consist of physiologically 
well-tolerated ingredients and they have good storage capa-
bilities after lyophilization and/or sterilization. When injected 
intravenously, SLN are sufﬁ  ciently small to circulate in the 
microvascular system and prevent macrophage uptake in 
case of hydrophilic coating. Therefore, SLN have been sug-
gested for viral and non-viral gene delivery. Cationic SLN 
has been demonstrated to bind genes directly via electrostatic 
interactions, and to have potential beneﬁ  ts in targeted gene 
therapy in treatment of cancer. The charge of particles can 
also be modulated via the composition, thus allowing binding 
of oppositely charged molecules (Olbrich et al 2001; Tabatt 
et al 2004; Pedersen et al 2006). Moreover, coating of SLN 
with PEG increases stability and plasma half life of SLN in 
order to decrease phagocytic uptake, and therefore improves 
the biovailability of drugs.
Treatment of central nervous system diseases such as brain 
tumors, AIDS, neurological and psychiatric disorders is often 
constrained by the inability of potent drugs to pass blood-
brain barrier (BBB), which is formed by the endothelium of 
the brain vessels, the basal membrane and neurological cells. 
Hydrophilic coating of colloids improves the transport of these 
through BBB and tissue distribution (Kreuter 2001; Wang et al 
2002). Various researchers also reported that tumor microves-
sels were more permeable to macromolecules than normal 
blood vessels, and their lower selectivity to permeability was 
presumably due to larger pores in the vessel walls (Yuan et 
al 1995). Fundaro et al (2000) prepared doxorubicin loaded 
stealth and non-stealth SLN. They used PEG 2000 to stabilize 
stearic acid SLN and to modify their surface. They observed 
that the stealth nanoparticles were present in blood at higher 
concentrations than non-stealth SLN after 24 h following iv 
administration. Doxorubicin was determined at a detectable 
concentration in the brain only after administration of stealth 
SLN. The drug was more easily transported through the BBB 
in this case. Stealth SLN showed a lower clearance, a higher 
distribution volume, and a signiﬁ  cantly higher AUC than non-
stealth SLN. In the same study, doxorubicin concentration in 
tissues was determined to be higher in the lung and brain with 
stealth SLN, and in the liver, heart, kidney and spleen with 
non-stealth SLN. The decreased uptake by RES tissues (such as 
spleen and liver) of SLN increased the drug bioavailability in 
non-RES tissue targeting. Researchers have demonstrated that 
coated SLN with hydrophilic molecules carrying anticancer 
drugs can reach cancer cells in solid tumors more effectively 
than healthy tissues.
In general, parenteral application of SLN reduces the 
possible side effects of drug incorporated with increased 
bioavailability. These systems are very suitable for drug 
targeting. Excellent properties of SLN make them attractive 
drug carrier systems even for pharmaceutical companies. SLN 
products of several pharmaceutical companies can be given 
as follows: cationic solid lipid nanoparticles (SLN) for gene 
transfer namely TransoPlex® was produced by PharmaSol DDS 
(Germany) (Olbrich et al 2001; www.pharmasol-berlin.de). 
AlphaRx (USA) is developing vancomycin and gentami-
cin products with VansolinTM and ZysolinTM trade names 
(www.alpharx.com). They are very effective in treatment 
of life-threatening infectious disease such as pneumonia. 
The intention of incorporating them into SLN has been to 
increase their efﬁ  cacy while reducing their side effects. 
SkyePharma (UK) also have formulations of nanoparticulate 
technology which includes nanosuspensions and solid lipid 
nanoparticles under preclinical development (Powers 2005; 
www.skyepharma.com).
Oral administration
The use of submicron-size particular systems in oral drug 
delivery, especially peptide drugs, has attracted consider-
able pharmaceutical interest. Controlled release behavior 
of these systems is reported to enable the bypass of gastric 
and intestinal degradation of the encapsulated drug (Damgé 
et al 1990; Olbrich et al 2002), and their possible uptake and 
transport through the intestinal mucosa (Tobio et al 2000). 
However, the assessment of the stability of colloidal carriers 
in GI ﬂ  uids is essential in order to predict their suitability 
for oral administration. Critical parameters have been widely 
overlooked in the design of new and efﬁ  cent colloidal drug 
carrier systems for oral use: I) their stability upon contact with 
GI ﬂ  uids since they are composed of biodegredable materials 
and particle size in nanorange maximizes the surface area 
for enzymatic degradation (Müller et al 1996b), II) particle 
aggregation due to environmental conditions of the GI tract 
leading decrease in the interaction capability of particles with 
the intestinal mucosa (Jani et al 1990).
The oral administration of SLN has been performed, 
but no data has been published so far concerning stability 
of SLN in the GI tract. SLN were introduced as a novel 
drug carrier system for oral delivery in the middle of 1990s 
(Runge et al 1996). The adhesive properties of nanoparticles 
are reported to increase bioavailability and reduce or mini-
mize erratic absorption (Ponchel et al 1997). Absorption of 
nanoparticles occurs through mucosa of the intestine by 
several mechanisms, namely through the Peyer’s patches, 
by intracellular uptake or by the paracellular pathway. Pinto 
and Müller (1999) incorporated SLN into spherical pellets International Journal of Nanomedicine 2007:2(3) 296
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and investigated SLN release for oral administration. SLN 
granulates or powders can be put into capsules, compressed 
into tablets or incorporated into pellets. For some of these 
applications, the conversion of the liquid dispersion into a dry 
product by spray-drying or lyophilization is useful, or often 
necessary (Freitas and Müller 1998; Pinto and Müller 1999). 
In an upcoming study, the inﬂ  uence of artiﬁ  cial GI media on 
the physical stability of SLN formulations was investigated 
and it was concluded that it was possible to produce stable 
SLN dispersions by optimizing the ingredients in the formula-
tion (Zimmermann and Müller 2001). Tobramycin which is 
not absorbed in solution form, was incorporated into SLN 
(Bargoni et al 2001). SLN changed the pharmacokinetics 
of the drug after being administered to rats by the duodenal 
route. AUC was higher than that of tobramycin in SLN or in 
solution administered by the iv route.
Hydrophilic coating as a successful technique provides 
protection of biodegradable colloidal carriers from enzymatic 
degradation and aggregation, favours the interaction with 
epithelia, thus prolonging the efﬁ  ciency of drugs. Antituber-
cular drugs (rifampicin, isoniazid and pyrazinamide) were 
entrapped into polyvinyl alcohol coated SLN and following 
a single oral administration to mice, therapeutic drug con-
centrations were maintained in the plasma for 8 days and 
in the organs (lungs, liver and spleen) for 10 days (Pandey 
et al 2005). A recent report of Garcia-Fuentes et al (2002) 
showed that the surface modiﬁ  cation with PEG-stearate led 
to a signiﬁ  cant improvement in the stability and resistance to 
lipolytic enzymes. Various studies have indicated that PEG 
coating of colloids leads to increased attention to their oral 
use, especially in delivery of peptide drugs. For instance, 
oral calcitonin delivery via SLN was attempted by coating 
particles with hydrophilic substances including PEG (Garcia-
Fuentes et al 2005a and 2005b). The results showed that the 
nature of the coating might affect the surface association and, 
hence, the immediate release of the peptide. It could provide 
a continuous delivery of the associated peptide and improved 
the drug bioavailability.
Various companies are interested in solid lipid nanotech-
nology for oral drug delivery. Pharmatec (Italy) developed 
a cyclosporine SLN formulation for oral administration 
(Müller et al 1998; Radtke and Müller 2001). Avoidance 
of high plasma peak and low variability in plasma proﬁ  le 
were provided in this case. AlphaRx have also rifampi-
cin-loaded SLN under preclinical phase (RifamsolinTM) 
(www.alpharx.com). Rifampicin is mainly used to treat 
tuberculosis, which requires long-term treatment due to poor 
cellular antibiotic penetration. AlphaRx aims to deliver this 
drug inside the human cell, to increase its efﬁ  cacy and as a 
result to increase patient compliance.
Rectal administration
When rapid pharmacological effect is required, in some 
circumstances, parenteral or rectal administration is pre-
ferred. Conventional rectal delivery of drugs is also very 
often used for pediatric patients all over the world due to easy 
application. In the meantime, plasma levels and therapeutic 
efﬁ  cacy of rectally administered drugs were reported to be 
higher compared with those given orally or intramuscularly 
in the same dose (Kanto 1975; Sznitowska et al 2001). A 
few reports are available on the rectal drug administration 
via SLN in the literature (Sznitowska et al 2000). Sznitowska 
et al (2001) incorporated diazepam into SLN for rectal ad-
ministration in order to provide a rapid action. They applied 
SLN dispersions on rabbits and performed bioavailability 
studies. They found that lipid matrix which is solid at body 
temperature is not an advantageous system for diazepam 
rectal delivery. They decided to employ lipids which melt 
around body temperature in their next experiments. This 
area seems very open to investigation, especially when the 
beneﬁ  ts of rectal route are taken into consideration. PEG 
coating seems to be a promising approach on rectal delivery 
and consequently, enhancement of bioavailability.
Nasal administration
Nasal administration was a promising alternative non-
invasive route of drug administration due to fast absorption 
and rapid onset of drug action, avoiding degradation of 
labile drugs (such as peptides and proteins) in the GI tract 
and insufﬁ  cient transport across epithelial cell layers (Lee 
et al 1994). In order to improve drug absorption through the 
nasal mucosa, approaches such as formulation development 
and prodrug derivatization have been employed. SLN has 
been proposed as alternative transmucosal delivery systems 
of macromolecular therapeutic agents and diagnostics by 
various research groups (Müller and Keck 2004; Prego et 
al 2005). Additionally, hydrophilic coating of SLN will 
permit the interaction and transport of SLN through the nasal 
mucosa and therefore bring great beneﬁ  ts and compliance as 
nasal drug carriers especially for vaccines. In a recent report, 
coating polymeric nanoparticles with PEG gave promising 
results as vaccine carriers (Vila et al 2004). Hydrophilic par-
ticles are preferable to hydrophobic ones in terms of their util-
ity as mucosal carriers. The role of PEG coating of polylactic 
acid nanoparticles in improving the transmucosal transport 
of the encapsulated bioactive molecules was reported to be International Journal of Nanomedicine 2007:2(3) 297
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successful by Tobio et al (1998). This concept can be useful 
for solid lipid nanoparticles.
Respiratory delivery
The lungs offer a high surface area for drug absorption by 
avoiding ﬁ  rst-pass effects. Rapid drug absorption by aero-
solization of drugs (in the 1–3 μm size range) occurs since 
the walls of alveoli in the deep lung are extremely thin (Agu 
et al 2001; Banga 2003). The nebulization of SLN is a new 
and upcoming area of research. Lymphatic drainage plays an 
important role in the uptake of particulates in the respiratory 
system. SLN can be proposed as carriers of anticancer drugs 
in lung cancer treatment or peptide drugs to improve their 
bioavailability. Assessment of inhaled radio-labelled SLN 
biodistribution has been described and the data showed an 
important and signiﬁ  cant uptake of the radio-labelled SLN 
into the lymphatics after inhalation (Videira et al 2002). A 
high rate of distribution in periaortic, axillar and inguinal 
lymph nodes was observed indicating that SLN could be 
effective colloidal carriers for lymphoscintigraphy or therapy 
upon pulmonary delivery. In a recent study, antitubercular 
drugs (rifampicin, isoniazid and pyrazinamide) were incorpo-
rated into various formulations of solid lipid particles ranged 
from 1.1–2.1 μm and formulations were nebulized to guinea 
pigs by mouth for direct pulmonar delivery (Pandey and 
Khuller 2005). Nebulization of solid lipid particles carrying 
antitubercular drugs was observed to be successful in improv-
ing drug bioavailability and reducing the dosing frequency 
for better management of pulmonary tuberculosis. 
Ocular administration
Colloidal drug delivery systems are considered to enhance 
the ocular bioavailability of drugs (De Campos 2001; 
Barbault-Foucher et al 2002; Ludwig 2005). Polymeric 
nanoparticles have been prepared for this aim, even beneﬁ  ts 
of PEG coating on the bioavailability has been investigated. 
The importance of surface characteristics of nanoparticles 
in their interaction with ocular mucosa has been discussed 
(De Campos et al 2003). Ocular drug administration via SLN 
has been reported several times (Cavalli et al 1995; Friedrich 
et al 2005). Biocompatibility and muco-adhesive properties 
of SLN improve their interaction with ocular mucosa and 
prolong corneal residence time of the drug, with the aim of 
ocular drug targeting. Cavalli et al (2002) evaluated SLN 
as carriers for ocular delivery of tobramycin in rabbit eyes. 
Drug concentration in the aqueous humor was determined 
up to six hours. As a result SLN signiﬁ  cantly enhanced the 
drug bioavalability in the aqueous humor. Cavalli et al (1995) 
also studied pilocarpin delivery via SLN which is commonly 
used in glaucoma treatment, earlier. They reported very 
similar results in order to enhance the ocular bioavailability 
of drug.
Another research group incorporated poorly water-
soluble drugs (hydrocortisone, estradiol hemihydrate and 
pilocarpine base) into SLN and performed in vitro drug 
permeation study through human organotypical cornea 
construct (Friedrich et al 2005). They observed high loading 
capacity, because drugs were nearly completely incorporated 
within the nanoparticles due to their high lipophilic character. 
Consequently, permeation studies indicated prolonged drug 
release in all the formulations.
In industrial ﬁ  elds, the incorporation of several antibiotics 
has been attempted in SLN, due to their broad antimicrobial 
spectrum. For an instance, OcusolinTM from AlphaRx is a 
gentamicin loaded-SLN product in the form of ophthalmic 
solution. It is still under preclinical development (www.
alpharx.com).
Topical application
SLN and NLC are very attractive colloidal carrier systems for 
skin applications due to their various desirable effects on skin 
besides the characteristics of a colloidal carrier system. They 
are well suited for use on damaged or inﬂ  amed skin because 
they are based on non-irritant and non-toxic lipids (Wissing 
and Müller 2003). Researchers have reported intensively on 
the topical application of SLN. During the last few years, 
SLN and NLC have been studied with active compounds 
such as vitamin E (Dingler et al 1999), tocopherol acetate 
(Wissing and Müller 2001), retinol (Jenning et al 2000a), 
ascorbyl palmitate (Üner et al 2005a and 2005b), clotrimazole 
(Souto et al 2004), triptolide (Mei et al 2003), phodphyllo-
toxin (Chen et al 2006) and a nonsteroidal antiandrogen RU 
58841 (Münster et al 2005) for topical application.
Chemisches Laboratorium Dr. Kurt Richter (Germany) 
introduced a NCL formulation containing black currant seed 
oil for regenerative care of scaly and aged skin (NanoLipid 
RestoreTM) in the German market (www.clr-berlin.de).
Conclusion
SLN constitute an attractive colloidal drug carrier system due 
to successful incorporation of active compounds and their 
related beneﬁ  ts. Their beneﬁ  ts are still being demonstrated 
and new approaches are introduced. SLN offer an economi-
cal and patient-friendly device for administration of drugs by 
various routes. Coating of SLN with hydrophilic substances 
is very promising in the treatment of various diseases such International Journal of Nanomedicine 2007:2(3) 298
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as cancer and tuberculosis. Reports on surface modiﬁ  cation 
of SLN by PEG coating have distinctly increased attention 
of various research groups with the aim of improving drug 
bioavailability. The concept of surface modiﬁ  cation is further 
increasing the importance of SLN among traditional colloidal 
drug carrier systems.
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